SEARCH

SEARCH BY CITATION

References

  • Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP et al. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116: 304313.
  • Abes S, Turner J, Ivanova GD, Owen D, Williams D, Arzumanov A et al. (2007). Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 35: 44954502.
  • Aoshiba K, Yokohori N, Nagai A (2003). Alveolar wall apoptosis causes lung destruction and amphysematous changes. Am J Respir Cell Mol Biol 28: 555561.
  • Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S et al. (2003). A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63: 39313939.
  • Beauvais DM, Rapraeger AC (2004). Syndecans in tumor cell adhesion and signalling. Reprod Biol Endocrinol 2: 35.
  • Bowne WB, Michl J, Bluth MH, Zenilman ME, Pincus MR (2007). Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. Cancer Ther 5B: 331344.
  • Branden LJ, Mohamed AJ, Smith CI (1999). A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 17: 784787.
  • Bright R, Raval AP, Dembner JM, Pérez-Pinzón MA, Steinberg GK, Yenari MA et al. (2004). Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci 24: 68806888.
  • Burrer R, Neuman BW, Ting JP, Stein DA, Moulton HM, Iversen PL, et al. (2007). Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J Virol 81: 56375648.
  • Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR et al. (2002). In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22: 54235431.
  • Cartier R, Reszka R (2002). Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther 9: 157163.
  • Chen L, Harrison SD (2007). Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem Soc Trans 35: 821825.
  • Conner SD, Schmid SL (2003). Regulated portals of entry into the cell. Nature 422: 3744.
  • Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K (2003). Antennapedia and HIV transactivator of transcription (TAT) ‘protein transduction domains’ promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278: 3510935114.
  • Couchman JR (2003). Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 4: 926937.
  • Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G (2007). A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans 35: 4446.
  • Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA et al. (2004). Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 10: 1004010046.
  • De Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J (2007). Interfering with desease: a progress report on siRNA-based therapeutics. Nat Rev Drug Disc 6: 443453.
  • Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 1044410450.
  • Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F (2004a). Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry 43: 14491457.
  • Deshayes S, Gerbal-Chaloin S, Morris MC, Aldrian-Herrada G, Charnet P, Divita G et al. (2004b). On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 1667: 141147.
  • Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C, Heitz F (2004c). Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 43: 76987706.
  • Deshayes S, Morris MC, Divita G, Heitz F (2005). Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 62: 18391849.
  • Deshayes S, Morris M, Heitz F, Divita G (2008). Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 60: 537547.
  • Dietz GP, Bähr M (2004). Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 27: 85131.
  • Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R (2007). A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8: 848866.
  • Eitzen G (2003). Actin remodelling to facilitate membrane fusion. Biochim Biophys Acta 1641: 175181.
  • El-Andaloussi S, Holm T, Langel Ü (2005). Cell-penetrating peptides: mechanism and applications. Cur Pharma Design 11: 35973611.
  • Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494498.
  • Elliott G, O'Hare P (1997). Intercellular trafficking and protein delivery by a Herpesvirus structural protein. Cell 88: 223233.
  • Elmquist A, Lindgren M, Bartfai T, Langel U (2001). VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 269: 237244.
  • Esbjorner EK, Gräslung A, Nordën P (2007). Membrane interactions of cell penetrating peptide. In: LangelÜ (ed.). Cell-Penetrating Peptides. CRC press: Boca Raton, FL, pp. 109138.
  • Escriou V, Carriere M, Scherman D, Wils P (2003). NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv Drug Deliv Rev 55: 295306.
  • Eum WS, Kim DW, Hwang IK, Yoo KY, Kang TC, Jang SH et al. (2004). In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic Biol Med 37: 16561669.
  • Fabani MM, Ivanova GD, Gait MJ (2008). Peptide-Peptide Nucleic Acid conjugates for modulation of gene expression. In: KurreckJ (ed.). Therapeutic Oligonucleotide. Royal Society of Chemistry: Cambridge, pp. 80102.
  • Farrera-Sinfreu J, Giralt E, Royo M, Albericio F (2007). Cell-penetrating proline-rich peptidomimetics. Methods Mol Biol 386: 241267.
  • Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B et al. (1994). Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91: 664668.
  • Fischer R, Fotin-Mleczek M, Hufnagel H, Brock R (2005). Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem 6: 21262142.
  • Fisher L, Soomets U, Cortés Toro V, Chilton L, Jiang Y, Langel U, Iverfeldt K (2004). Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Ther 11: 12641272.
  • Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP et al. (2007). Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 15: 15871592.
  • Foerg C, Merkle HP (2008). On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 97: 144162.
  • Frankel AD, Pabo CO (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 11891193.
  • Fulda S, Wick W, Weller M, Debatin KM (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808815.
  • Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K et al. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276: 58365840.
  • Gait MJ (2003). Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell Mol Life Sci 60: 844853.
  • Gallo G (2003). Making proteins into drugs: assisted delivery of proteins and peptides into living neurons. Methods Cell Biol 71: 325338.
  • Gallo G, Yee HF, Letourneau PC (2002). Actin turnover is required to prevent axon retraction driven by endogenous actomyosin contractility. J Cell Biol 158: 12191228.
  • Gerbal-Chaloin S, Gondeau C, Aldrian-Herrada G, Heitz F, Gauthier-Rouvière C, Divita G (2007). First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network Remodelling. Biol Cell 99: 223238.
  • Glover DJ, Lipps HJ, Jans DA (2005). Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6: 299310.
  • Gondeau C, Gerbal-Chaloin S, Bello P, Aldrian-Herrada G, Morris MC, Divita G (2005). Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J Biol Chem 280: 1379313800.
  • Gottschalk S, Sparrow JT, Hauer J, Mims MP, Leland FE, Woo SL, et al. (1996). A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther 3: 448457.
  • Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F et al. (2006). A non-covalent peptide-based strategy for protein and peptide nucleic acid delivery. Biochim Biophys Acta 1758: 384393.
  • Gryaznov S, Asai A, Oshima Y, Yamamoto Y, Pongracz K, Pruzan R, et al. (2003). Oligonucleotide N3′–> P5′ thio-phosphoramidate telomerase template antagonists as potential anticancer agents. Nucleosides Nucleotides Nucleic Acids 22: 577581.
  • Hannon GJ (2002). RNA interference. Nature 418: 244251.
  • Hosotani R, Miyamoto Y, Fujimoto K, Doi R, Otaka A, Fujii N et al. (2002). Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res 8: 12711276.
  • Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV et al. (2003). Complexes of plasmid DNA with basic domain 47–57.of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem 278: 4262542636.
  • Järver P, Langel Ü (2004). The use of cell-penetrating peptides as a toll for gene regulation. Drug Discov Today 9: 395402.
  • Joliot A, Prochiantz A (2004). Transduction peptides: from technology to physiology. Nat Cell Biol 6: 189196.
  • Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A (1991). Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 88: 18641868.
  • Juliano R, Alam MR, Dixit V, Kang H (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36: 41584171.
  • Kaplan IM, Wadia JS, Dowdy SF (2005). Cationic Tat peptide transduction domain enters cells by macropinocytosis. J Control Release 102: 247253.
  • Kichler A, Leborgne C, März J, Danos O, Bechinger B (2003). Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc Natl Acad Sci USA 100: 15641568.
  • Kilk K, El-Andaloussi S, Järver P, Meikas A, Valkna A, Bartfai T et al. (2005). Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J Control Release 103: 511523.
  • Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, Abarzua P et al. (1999). Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 274: 3492434931.
  • Kim WJ, Christensen LV, Jo S, Yockman JW, Jeong JH, Kim YH et al. (2006). Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 14: 343350.
  • Knight JS, Lan K, Bajaj B, Sharma N, Tsai DE, Robertson ES (2006). A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein-Barr virus. Virology 354: 207214.
  • Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H (2004). Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 98: 317323.
  • Kong H, Mooney DJ (2007). Microenvironmental regulation of biomacromolecular therapies. Nat Rev Drug Discov 6: 455463.
  • Koppelhus U, Nielsen PE (2003). Cellular Delivery of peptide nucleic acid. Adv Drug Del Rev 55: 267280.
  • Koppelhus U, Awasthi SK, Zachar V, Holst HU, Ebbesen P, Nielsen PE (2002). Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 12: 5163.
  • Krauss U, Muller M, Stahl M, Beck-Sickinger AG (2004). In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide. Bioorg Med Chem Lett 14: 5165.
  • Krautwald S, Ziegler E, Tiede K, Pust R, Kunzendorf U (2004). Transduction of the TAT-FLIP fusion protein results in transient resistance to Fas-induced apoptosis in vivo. J Biol Chem 277: 4400544011.
  • Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 7149: 3943.
  • Lear JD, DeGrado WF (1987). Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA-2. J Biol Chem 262: 65006510.
  • Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA et al. (2008). Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 60: 517529.
  • Lee HL, Dubikovskaya EA, Hwang H, Semyonov AN, Wang H, Jones LR et al. (2008). Single-molecule motions of oligoarginine transporter conjugates on the plasma membrane of Chinese hamster ovary cells. J Am Chem Soc 130: 93649370.
  • Lundberg M, Johansson M (2001). Is VP22 nuclear homing an artefact? Nat Biotechnol 19: 713714.
  • Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. (2007). Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 11: 26642671.
  • MacKay JA, Li W, Huang Z, Dy EE, Huynh G, Tihan T et al. (2008). HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery. Mol Ther 16: 893900.
  • Magzoub M, Gräslund A (2004). Cell-penetrating peptides: small from inception to application. Q Rev Biophys 37: 147195.
  • Maron MB, Folkesson HG, Stader SM, Walro JM (2005). PKA delivery to the distal lung air spaces increases alveolar liquid clearance after isoproterenol-induced alveolar epithelial PKA desensitization. Am J Physiol Lung Cell Mol Physiol 289: 349354.
  • Marthinet E, Divita G, Bernaud J, Rigal D, Baggetto LG (2000). Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter. Gene Ther 7: 12241233.
  • Meade BR, Dowdy SF (2007). Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59: 134140.
  • Melnick A (2007). Targeting aggressive B-cell lymphomas with cell-penetrating peptides. Biochem Soc Trans 35: 802806.
  • Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, Von Gizycki H et al. (2006). PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer 119: 15771585.
  • Midoux P, Kichler A, Boutin V, Maurizot JC, Monsigny M (1998). Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem 9: 260267.
  • Morris KV, Chan SW, Jacobsen SE, Looney DJ (2004a). Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305: 12891292.
  • Morris MC, Vidal P, Chaloin L, Heitz F, Divita G (1997). A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25: 27302736.
  • Morris MC, Chaloin L, Mery J, Heitz F, Divita G (1999). A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res 27: 35103517.
  • Morris MC, Chaloin L, Heitz F, Divita G (2000). Translocating peptides and proteins and their use for gene delivery. Curr Opin Biotechnol 11: 461466.
  • Morris MC, Depollier J, Mery J, Heitz F, Divita G (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19: 11731176.
  • Morris MC, Chaloin L, Choob M, Archdeacon J, Heitz F, Divita G (2004b). Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression. Gene Ther 11: 757764.
  • Morris MC, Deshayes S, Simeoni F, Aldrian-Herrada G, Heitz F, Divita G (2007a). A noncovalent peptide-based strategy for peptide and short interfering RNA delivery. In: LangelÜ (ed.). Cell-Penetrating Peptides. CRC press: Boca Raton, FL, pp. 387408.
  • Morris MC, Gros E, Aldrian-Herrada G, Choob M, Archdeacon J, Heitz F et al. (2007b). A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 35: e49e59.
  • Morris MC, Deshayes S, Heitz F, Divita G (2008). Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 100: 201217.
  • Moschos S, Williams A, Lindsay M (2007). In vivo applications of Cell-Penetrating peptide. In: LangelÜ (ed.). Cell-Penetrating Peptides. CRC press: Boca Raton, FL, pp. 423438.
  • Moulton HM, Moulton JD (2004). Arginine-rich cell-penetrating peptides with uncharged antisense oligomers. Drug Discov Today 9: 870875.
  • Moulton HM, Moulton JD (2008). Antisense morpholino oligomers and theirs peptide conjugates. In: KurreckJ (ed.). Therapeutic Oligonucleotide. Royal Society of Chemistry: Cambridge, pp. 4379.
  • Munoz-Morris MA, Heitz F, Divita G, Morris MC (2007). The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem Biophys Res Commun 355: 877882.
  • Muratovska A, Eccles MR (2004). Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558: 6368.
  • Murriel CL, Dowdy SF (2006). Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv 3: 739746.
  • Myou S, Leff AR, Myo S, Boetticher E, Meliton AY, Lambertino AT et al. (2003). Activation of group IV cytosolic phospholipase A2 in human eosinophils by phosphoinositide 3-kinase through a mitogen-activated protein kinase-independent pathway. J Immunol 171: 43994405.
  • Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA et al. (1998). Transduction of full-length TAT fusion proteins into mammalian cells: TAp27kip1 induced cell migration. Nat Med 4: 14491453.
  • Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y et al. (2004). Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 10: 10111022.
  • Nakase I, Tadokoro A, Kawabata N, Takeuchi T, Katoh H, Hiramoto K, et al. (2007). Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 46: 492501.
  • Nan L, Wu Y, Bardag-Gorce F, Li J, French BA, Wilson L et al. (2005). RNA interference of VCP/p97 increases Mallory body formation. Exp Mol Pathol 78: 19.
  • Nguyen QN, Chavli RV, Marques JT, Jr, Conrad PG, Wang D, He W et al. (2006). Light controllable siRNAs regulate gene suppression and phenotypes in cells. Biochim Biophys Acta 1758: 394403.
  • Niidome T, Huang L (2002). Gene therapy progress and prospects: non viral vectors. Gene Ther 10: 16471652.
  • Ogris M, Wagner E (2002). Targeting tumors with non-viral gene delivery systems. Drug Discov Today 7: 479485.
  • Opalinska JB, Gewirtz AM (2002). Nucleic-acid therapeutics: basic principles and recent applications. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1: 503516.
  • Padari K, Saalik P, Hansen M, Koppel K, Raid R, Langel U et al. (2005). Cell transduction pathways of transportans. Bioconjug Chem 16: 13991410.
  • Parente RA, Nadasdi L, Subbarao NK, Szoka FC Jr. (1990). Association of a pH-sensitive peptide with membrane vesicles: role of amino acid sequence. Biochemistry 29: 87138719.
  • Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC (2000). Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad USA 97: 82458250.
  • Park IY, Park CB, Kim MS, Kim SC, Parasin I (1998). An antimicrobial peptide derived from histone H2A in the catfish, Parasilurus asotus. FEBS Lett 437: 258262.
  • Patel LN, Zaro JL, Shen WC (2007). Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 24: 19771992.
  • Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF et al. (2004). Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10: 13291335.
  • Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K et al. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 16: 857861.
  • Pooga M, Kut C, Kihlmark M, Hallbrink M, Fernaeus S, Raid R et al. (2001). Cellular translocation of proteins by transportan. FASEB J 8: 14511453.
  • Pujals S, Fernandez-Carneado J, Lopez-Iglesias C, Kogan MJ, Giralt E (2006). Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta 1758: 264279.
  • Rhyner C, Kündig T, Akdis CA, Crameri R (2007). Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 35(Pt 4): 833834.
  • Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ et al. (2003). Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585590.
  • Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik V (2005). Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280: 1530015306.
  • Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R et al. (2002). New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 5: 104114.
  • Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA (2004). Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 126: 95069507.
  • Rousselle C, Smirnova M, Clair P, Lefauconnier JM, Chavanieu A, Calas B et al. (2001). Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 296: 124131.
  • Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J (2003). Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 278: 1141111418.
  • Rusnati M, Tulipano G, Spillmann D, Tanghetti E, Oreste P, Zoppetti G et al. (1999). Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J Biol Chem 274: 2819828205.
  • Schmidt MC, Rothen-Rutishauser B, Rist B, Beck-Sickinger A, Wunderli-Allenspach H, Rubas W et al. (1998). Translocation of human calcitonin in respiratory nasal epithelium is associated with self assembly in lipid membrane. Biochemistry 37: 1658216590.
  • Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 15691572.
  • Simeoni F, Morris MC, Heitz F, Divita G (2003). Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31: 27172724.
  • Snyder EL, Dowdy SF (2005). Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2: 4351.
  • Snyder EL, Meade BR, Saenz CC, Dowdy SF (2004). Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2: E36. .
  • Sugioka R, Shimizu S, Funatsu T, Tamagawa H, Sawa Y, Kawakami T et al. (2003). BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 22: 84328440.
  • Tang X, Molina M, Amar S (2007). p53 short peptide regulateds lipopolysaccharide – induced tumor necrosis factor-a-factor/cytokine expression. Cancer Res 67: 13081316.
  • Terrone D, Sang SL, Roudaia L, Silvius JR (2003). Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry 42: 1378713799.
  • Thoren PE, Persson D, Isakson P, Goksor M, Onfelt A, Norden B (2003). Uptake of analogs of penetratin, Tat(48–60) and oligoarginine in live cells. Biochem Biophys Res Commun 307: 100107.
  • Thyner C, Kündig T, Akdis CA, Crameri R (2007). Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 35: 833844.
  • Torchilin VP (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145160.
  • Torchilin VP (2008). Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60: 548558.
  • Tung CH, Mueller S, Weissleder R (2002). Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem 10: 36093614.
  • Veldhoen S, Laufer SD, Trampe A, Restle T (2006). Cellular delivery of small interfering RNA by a noncovalenty attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 34: 65616573.
  • Vives E, Brodin P, Lebleu B (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 1601016017.
  • Vivès E, Schmidt J, Pèlegrin A (2008). Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786: 126138.
  • Wadia J, Stan RV, Dowdy S (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310315.
  • Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB (2000). The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 97: 1300313008.
  • Wender PA, Goun EA, Jones LR, Pillow TH, Rothbard JB, Shinde R et al. (2007). Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice. Proc Natl Acad Sci USA 104: 1034010345.
  • Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC Jr. (1997). Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 36: 30083017.
  • Zatsepin TS, Turner JJ, Oretskaya TS, Gait MJ (2005). Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing. Curr Pharmaceutical Design 11: 36393654.
  • Zeineddine D, Papadimou E, Chebli K, Gineste M, Liu J, Grey C et al. (2006). Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. Dev Cell 11: 535546.
  • Ziegler A (2008). Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev 60: 580597.
  • Ziegler A, Nervi P, Dürrenberger M, Seelig J (2005). The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry 44: 138148.